European Union’s share of global medicine R&D shrinks by 25% in 20 years 25 Nov 2022
A report commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA) has led the organisation to warn that the options being discussed by policymakers around the EU Pharma Strategy fall short. The publication states that world-leading hubs, including the UK’s Golden Triangle, ‘receive significant policy focus and strategic funding’, while European research funding is ‘more uniform, prioritising equality over quality’.
Read more.